Specific and off-target immune responses following COVID-19 vaccination with ChAdOx1-S and BNT162b2 vaccines—an exploratory sub-study of the BRACE trial
journal contribution
posted on 2024-05-09, 02:43authored byNL Messina, S Germano, R McElroy, R Bonnici, B Grubor-Bauk, DJ Lynn, E McDonald, S Nicholson, KP Perrett, LF Pittet, R Rudraraju, NE Stevens, K Subbarao, N Curtis, A Davidson, K Gardiner, A Gwee, T Jamieson, N Messina, T Morawakage, Susan PerlenSusan Perlen, K Perrett, L Pittet, A Sastry, JW Teo, F Orsini, K Lee, C Moore, S Vidmar, R Ali, R Dunn, P Edler, G Gell, C Goodall, R Hall, A Krastev, N La, N McPhate, T Nguyen, J Ren, L Stevens, A Alamrousi, T Dang, J Hua, M Razmovska, S Reddiex, X Wang, J Anderson, K Azzopardi, V Bennett-Wood, A Czajko, N Mazarakis, C McCafferty, F Oppedisano, B Ortika, C Pell, L Spry, R Toh, S Velagapudi, A Vlahos, A Wee-Hee, P Ramos, K De La Cruz, D Gamage, A Karunanayake, I Mezzetti, B Ong, R Singh, E Sooriyarachchi, N Cain, R Brizuela, H Huang, V Abruzzo, M Bealing, P Bimboese, K Bowes, E Burrell, J Chan, J Cushnahan, H Elborough, O Elkington, K Fahey, M Fernandez, C Flynn, S Fowler, MG Andrit, B Gladanac, C Hammond, N Ma, S Macalister, E Milojevic, J Mojeed, J Nguyen, L O'Donnell, N Olivier, I Ooi, S Reynolds, L Shen, B Sherry, J Spotswood
Specific and off-target immune responses following COVID-19 vaccination with ChAdOx1-S and BNT162b2 vaccines—an exploratory sub-study of the BRACE trial